<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590289</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-5000-CL-103</org_study_id>
    <nct_id>NCT02590289</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects</brief_title>
  <official_title>An Open-Label, Single-Dose, 4-Way Crossover, Bioavailability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Food Effect of BBI-5000 Capsules in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brickell Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brickell Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacokinetics of 3 doses and the food effect of a single high dose of
      BBI-5000 capsules in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, 4-period, 4-way crossover, 4-sequence study to evaluate
      the pharmacokinetics (PK) and food effect of BBI-5000 capsules in healthy adult subjects.

      Participating subjects will receive a single oral dose of BBI-5000 followed by a washout
      period of 7-14 days between doses. The treatment period will be followed by 5-10 day
      follow-up period.

      PK and PD will be assessed by blood sampling through 72 hours postdose.

      Safety will be assessed through collection of vital signs, adverse events, physical
      examination, ECGs and clinical laboratory tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations after single dosing of BBI-5000 for BBI-5000 and 3 metabolites</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC) for BBI-5000 and 3 metabolites</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for BBI-5000 and 3 metabolites</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax)</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL/F)</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal plasma elimination rate constant for BBI-5000 and the 3 metabolites</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BBI-5000 concentrations in plasma after dosing in fed and fasted conditions</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life for BBI-5000 and the 3 metabolites</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by assessment of treatment-related adverse events, safety laboratory, vital signs, electrocardiogram and physical examination results</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Eosinophil shape change in whole blood as measured by dose and exposure-related dependent changes over time</measure>
    <time_frame>Week 4</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>BBI-5000 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose of BBI-5000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-5000 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose of BBI-5000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-5000 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of BBI-5000</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-5000 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose of BBI-5000</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-5000</intervention_name>
    <description>BBI-5000 low dose, middle dose, or high doses</description>
    <arm_group_label>BBI-5000 Dose 1</arm_group_label>
    <arm_group_label>BBI-5000 Dose 2</arm_group_label>
    <arm_group_label>BBI-5000 Dose 3</arm_group_label>
    <arm_group_label>BBI-5000 Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoker

          -  Medically healthy

          -  32.0 &gt;= BMI &gt;= 18.5 kg/m^2

          -  Weight &gt;= 50 kg for males

          -  Weight &gt;= 45 kg for females

          -  For a female of childbearing potential: either be sexually inactive for 14 days prior
             to the first dose and throughout the study or be using an acceptable birth control
             method as dictated by the study

          -  Willing to comply with protocol and understands study procedures outlined in the ICF

        Exclusion Criteria:

          -  Subject is mentally or legally incapacitated or has significant emotional problems

          -  History or presence of medical or psychiatric disease

          -  History of any illness that might confound the results of the study

          -  History or presence of alcoholism or drug abuse

          -  History or presence of hypersensitivity or idiosyncratic reaction the the study drug
             excipient

          -  History or presence of lactose intolerance

          -  Pregnant or lactating females

          -  Seated blood pressure less than 90/40 mmHg or greater than 140/90 mmHg

          -  Seated heart rate lower than 40 bpm or higher than 99 bpm

          -  Unable to refrain from or anticipates the use of any drug

          -  Diet incompatible with the on-study diet

          -  Donation of blood or significant blood loss within 56 days prior to the first study
             dose

          -  Participation in another clinical trial within 28 days prior to the first study dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Hussey, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Brickell Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Inc.</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

